Skip to content
Review Open access

Bacteriophage therapy in the era of antimicrobial resistance: clinical evidence, translational challenges, and emerging regulatory frameworks (2020–2026)

Aug 2026 · Exploration of Medicine · Vol 7 · 1 citation · 66 references

TL;DR

Routine clinical adoption of phage therapy will ultimately depend on outcomes of adequately powered confirmatory trials, alongside resolution of manufacturing, regulatory, and standardization challenges.

Abstract

Antimicrobial resistance has intensified the search for alternatives to conventional antibiotics, particularly against multidrug-resistant bacterial pathogens that increasingly compromise treatment outcomes in hospitals and community settings. This narrative review examines bacteriophage therapy as an alternative for combating multidrug-resistant bacteria. Recent literature is discussed thematically, with emphasis on original studies, clinical datasets, translational experiments, and regulatory documents. The current evidence base consists predominantly of compassionate-use reports, small cohorts, and early-phase trials, including CRISPR-enhanced and inhaled phage platforms, which report safety observations, compartment-specific responses, and microbiome effects in individual studies. Mechanistic considerations discussed in the review include route-specific delivery, phage–host ecological interactions, resistance trade-offs, and phage–antibiotic synergy. While microbiological and clinical responses have been reported in individual studies, no confirmatory randomized trial has demonstrated clinical efficacy for any phage therapy indication. Manufacturing, standardization, and regulatory pathways for scaled deployment also remain unresolved. Regulatory developments in Europe, the United Kingdom, the United States, and Australia remain heterogeneous and predominantly access-based or compassionate-use-based rather than approval-based. Specific technical challenges include incomplete standardization of susceptibility testing and the need for robust monitoring of immune neutralization, endotoxin burden, and long-term ecological effects. Routine clinical adoption of phage therapy will ultimately depend on outcomes of adequately powered confirmatory trials, alongside resolution of manufacturing, regulatory, and standardization challenges.

Read PDF

Similar papers

Review Open access Aug 2026

The Therapeutic Potential of Phages in Multi-Drug Resistance Infections and Future Directions

This review systematically analyzes major challenges restricting clinical application, such as standardized production, quality control, pharmacokinetic characterization, rapid pathogen identification, and regulatory adaptation, as well as the limited performance of fixed phage cocktails against genetically heterogeneo...

Sheng-Ting Zhang, Hui-Li Tao, Sha Zhao et al. · 0 citations
Review Open access Sep 2026

From laboratory to clinical application: a narrative review of bacteriophage therapy for antimicrobial-resistant infections in veterinary medicine

It is suggested that standardized, optimized bacteriophages may match the efficacy and biosafety of antibiotics, potentially enhancing their effectiveness in combination therapies.

Natália Chomová, G. Žoldák, D. Mudroňová · 0 citations
Review Sep 2026

Non-antibiotic therapeutic approaches for antimicrobial resistance: current evidence and future directions

This review summarizes the current evidence on non-antibiotic therapeutics including bacteriophages, antimicrobial peptides, anti-virulence agents, monoclonal antibodies, microbiome-based therapies, CRISPR-Cas systems, nanoparticles, photodynamic therapy, repurposed non-antibiotic drugs and combination strategies.

B. Ganesan, A. Mishra, D. Hota et al. · 0 citations
Review Open access Sep 2026

Bridging the gap between experimental evidence and clinical applications of antipseudomonal phage therapy against Pseudomonas aeruginosa.

Pseudomonas aeruginosa is one of the World Health Organization's (WHO) priority pathogens requiring urgent intervention because of its remarkable ability to develop antimicrobial resistance. The rapid emergence and global dissemination of multidrug-resistant P. aeruginosa have made the treatment of these infections inc...

Ahmed Elfadadny, W. Nageeb, Rokaia F. Ragab et al. · 0 citations
Review Open access Sep 2026

A novel alternative to the use of antimicrobials: Bacteriophages for combating antimicrobial resistance.

The rapid emergence of antimicrobial resistance poses a serious challenge to both human and veterinary medicine highlighting the urgent need to develop alternative antimicrobial strategies. Phage therapy has regained attention as a promising approach. However, its application in veterinary practice remains relatively l...

Shang-Le Feng, Shi-Yu Xie, Fang-Jing He et al. · 0 citations
Review Open access Sep 2026

Bacteriophages in the Age of Antibiotic Resistance: Therapeutic and Industrial Applications

The analysis indicates that phage therapy shows promising results, particularly for treating multidrug-resistant bacterial infections, and offers a powerful alternative to traditional antimicrobials due to their specificity and environmental friendliness.

Seda Özdikmenli Tepeli, K. Selvi · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.